Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegilodecakin + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
Pegilodecakin + pembrolizumab is a combination therapy that pairs two distinct immunotherapeutic agents. Pegilodecakin (pegylated IL-10) is a first-in-class, long-acting IL-10 receptor agonist that induces oligoclonal T-cell expansion and has anti-inflammatory and CD8+ T-cell stimulating properties. Pembrolizumab is an anti-PD-1 monoclonal antibody immune checkpoint inhibitor. The combination leverages complementary immune-enhancing mechanisms, with pegilodecakin stimulating CD8+ T-cells while pembrolizumab blocks the PD-1 pathway that cancer cells use to evade immune detection.
- Other names
- PEG + P
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IL10RA (Interleukin-10 Receptor)
Beyond the preview
Go deeper on pegilodecakin + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegilodecakin + pembrolizumab.